Finalized Dutch conditional reimbursement system imminent
This article was originally published in SRA
Formal criteria for what a Dutch conditional reimbursement system will finally look like are due to emerge at the end of the year, Nefarma, the Dutch pharmaceutical industry association says. However, delays in having a finalized system in place could be advantageous to companies with products that are at higher risk of losing reimbursement, said the association.
You may also be interested in...
England’s health technology appraisal body, NICE, and the UK medicines regulator, the MHRA, are working together to align their process timelines so that access to medicines is “maintained and enhanced.”
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.